关于申请向特定对象发行股票获得 深圳证券交易所上市审核中心审核通过的公告 证券代码：300143 证券简称：盈康生命 公告编号：2024-042 盈康生命科技股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 二〇二四年七月一日 特此公告。 盈康生命科技股份有限公司董事会 盈康生命科技股份有限公司（以下简称"公司"）于 2024 年 6 月 28 日收到 深圳证券交易所（以下简称"深交所"）上市审核中心出具的《关于盈康生命科 技股份有限公司申请向特定对象发行股票的审核中心意见告知函》。深交所发行 上市审核机构对公司向特定对象发行股票的申请文件进行了审核，认为公司符合 发行条件、上市条件和信息披露要求，后续深交所将按规定报中国证券监督管理 委员会（以下简称"中国证监会"）履行相关注册程序。 公司本次向特定对象发行股票事项尚需获得中国证监会作出同意注册的决 定后方可实施，最终能否获得中国证监会同意注册的决定及其时间尚存在不确定 性。公司将根据该事项的进展情况及时履行信息披露义务，敬请广大投资者谨慎 决策，注意投资风险。 ...

证券代码：300143 证券简称：盈康生命 公告编号：2024-041 盈康生命科技股份有限公司 关于股份回购完成暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 盈康生命科技股份有限公司（以下简称"公司"）于 2024 年 2 月 5 日召开第六 届董事会第六次（临时）会议审议通过了《关于回购公司股份方案的议案》，同意 公司使用自有资金以集中竞价交易方式回购公司已发行的人民币普通股（A 股）股 票，回购的股份将用于实施股权激励计划或员工持股计划。本次用于回购股份的资 金总额不低于人民币 4,000 万元且不超过人民币 8,000 万元（均含本数），回购价格 不超过人民币 13 元/股（含本数），回购期限自公司董事会审议通过本次回购股份 方案之日起 12 个月内。具体内容详见公司分别于 2024 年 2 月 6 日、2024 年 2 月 7 日在巨潮资讯网（www.cninfo.com.cn）披露的《关于回购公司股份方案的公告》及 《回购报告书》。 截至 2024 年 6 月 27 日，公司本次回购已实施完成。根据《上市公司股份回购 规则》《深 ...

证券简称：盈康生命 证券代码：300143 盈康生命科技股份有限公司 与 国泰君安证券股份有限公司 关于 申请向特定对象发行股票 的审核问询函的回复 （修订稿） 保荐人（主承销商） （中国（上海）自由贸易试验区商城路 618 号） 二〇二四年六月 深圳证券交易所： 根据深圳证券交易所上市审核中心 2023 年 12 月 12 日出具的《关于盈康生 命科技股份有限公司申请向特定对象发行股票的审核问询函》（审核函〔2023〕 020155 号）（以下简称"审核问询函"）的要求，盈康生命科技股份有限公司（以 下简称"盈康生命""发行人""上市公司"或"公司"）已会同国泰君安证券股 份有限公司（以下简称"保荐人"或"国泰君安"）、北京市金杜律师事务所（以 下简称"发行人律师"或"金杜"）及和信会计师事务所（特殊普通合伙）（以下 简称"发行人会计师"或"和信"）等中介机构本着勤勉尽责、诚实守信的原则， 对审核问询函所提出的问题进行了逐项落实，现将有关事项回复如下，请予以审 核。 说明： 除非文义另有所指，本回复中的简称或名词释义与募集说明书具有相同含义。 本回复报告的字体代表以下含义： | 审核问询函所列问题 | 黑体 ...

关于盈康生命科技股份有限公司 申请向特定对象发行股票的审核问询函回复 和信综字（2024）第 000280 号 和信会计师事务所（特殊普通合伙） 二○二四年六月二十五日 关于盈康生命科技股份有限公司 申请向特定对象发行股票的审核问询函回复 深圳证券交易所： 贵所2023年12月12日下发的《关于盈康生命科技股份有限公司申请向特定对 象发行股票的审核问询函》（审核函〔2023〕020155号）（以下简称"《审核问 询函》"）已收悉。根据贵所《审核问询函》提出的要求，本次发行上市审计机 构和信会计师事务所（特殊普通合伙）（以下简称"会计师"）就本次《审核问 询函》所提问题逐项进行了认真核查及分析说明，现就《审核问询函》中的有关 问题回复说明如下，请予以审核。 问题 2 截至 2023 年 9 月 30 日，发行人商誉账面价值为 5.83 亿元，包括收购苏州 广慈肿瘤医院有限公司（以下简称广慈医院）所形成的商誉 3.35 亿元、收购深 圳圣诺医疗设备股份有限公司（以下简称圣诺医疗）所形成的商誉 2.18 亿元。 剔除商誉减值影响，发行人净利润分别为 15,295.42 万元、9,481.24 万元、 7,213.3 ...

盈康生命科技股份有限公司 审计报告 和信审字(2024)第 000241 号 | | 目 录 | 贝 用 | | --- | --- | --- | | 0 | 一、审计报告 | 1-5 | | | 二、已审财务报表及附注 | | | ( | 1、合并及公司资产负债表 | 6-9 | | | 2、合并及公司利润表 | 10-11 | | | 3、合并及公司现金流量表 | 12-13 | | | 4、合并及公司股东权益变动表 | 14-17 | | | 5、财务报表附注 | 18-103 | | | 和信会计师事务所(特殊普通合伙) | | 二〇二四年四月十九日 6-1-1 0 0 0 | 0 O 0 盈康生命科技股份有限公司 告 揭 和信审字(2024)第 000241 号 盈康生命科技股份有限公司全体股东: 一、审计意见 我们审计了盈康生命科技股份有限公司(以下简称盈康生命)财务报表,包 括 2023年 12月 31日的合并及公司资产负债表,2023年度的合并及公司利润表、 合并及公司现金流量表、合并及公司股东权益变动表以及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制 ...

股票简称：盈康生命 股票代码：300143 盈康生命科技股份有限公司 Inkon Life Technology Co., Ltd. （青岛市城阳区春阳路 37 号） 2022 年度向特定对象发行股票 募集说明书 （二次修订稿） 保荐人（主承销商） （中国（上海）自由贸易试验区商城路 618 号） 二〇二四年六月 盈康生命科技股份有限公司 向特定对象发行股票募集说明书 声明 本公司及全体董事、监事、高级管理人员承诺募集说明书及其他信息披露资 料不存在任何虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性及完整 性承担相应的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财务 会计资料真实、完整。 中国证监会、深交所对本次发行所作的任何决定或意见，均不表明其对申请 文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反 的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担证券依法发行 ...

盈康生命科技股份有限公司 国泰君安证券股份有限公司 关于 向特定对象发行股票 之 发行保荐书 （中国（上海）自由贸易试验区商城路 618 号） 二〇二四年六月 保荐人关于本次证券发行的文件 发行保荐书 国泰君安证券股份有限公司 关于盈康生命科技股份有限公司 向特定对象发行股票之发行保荐书 国泰君安证券股份有限公司（以下简称"国泰君安""国泰君安证券"或"保 荐人"）接受盈康生命科技股份有限公司（以下简称"盈康生命""公司"或 "发行人"）的委托，担任盈康生命本次向特定对象发行股票（以下简称"本项 目"）的保荐人，毛宁、陈聪作为具体负责推荐的保荐代表人，为本次发行出具 发行保荐书。 保荐人及其指定的保荐代表人根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司证券发行注册管理办法》（以下简称"《注册管理办法》"）和《证 券发行上市保荐业务管理办法》（以下简称"《保荐业务管理办法》"）等有关 法律、法规和中国证券监督管理委员会（以下简称"中国证监会"）、深圳证券 交易所（以下简称"深交所"）的有关规定，诚实守信，勤勉尽责，严格按照依 法制订的业 ...

Company Overview - The total share capital of Inkon Life Technology Co., Ltd. is 642,167,010 shares as of March 31, 2024, with 100% being unrestricted shares[16]. - The company operates under a registered capital of 642.17 million yuan and was established on August 6, 1998, with its stock listed on December 9, 2010[14]. - The company is headquartered in Qingdao, Shandong Province, with its operational address at Haier Road, Qingdao[14]. - The company is involved in various business activities, including equity investment, enterprise management consulting, and software development[14]. Shareholder Information - The top ten shareholders hold a combined 50.20% of the company's shares, with the largest shareholder, Yingkang Medical Investment, owning 39.93%[18]. - As of March 31, 2024, the total share capital of the company is 642,167,010 shares, with Yingkang Medical Investment holding 39.93% and Haier Group indirectly controlling 41.66% of the company[20]. Financial Performance - For the first quarter of 2024, the company reported operating revenue of 41,623.09 million yuan, compared to 147,079.79 million yuan for the entire year of 2023[26]. - The net profit for the first quarter of 2024 is 2,605.72 million yuan, down from 9,919.85 million yuan in 2023[27]. - The total assets as of March 31, 2024, amount to 252,187.46 million yuan, an increase from 240,022.95 million yuan at the end of 2023[24]. - The total liabilities as of March 31, 2024, are 110,725.91 million yuan, compared to 97,141.91 million yuan at the end of 2023[24]. - The company's cash flow from operating activities for the first quarter of 2024 is 10,228.92 million yuan, compared to 19,001.25 million yuan for the entire year of 2023[28]. - The current ratio as of March 31, 2024, is 1.21, slightly up from 1.20 at the end of 2023[29]. - The debt-to-asset ratio (consolidated) as of March 31, 2024, is 43.91%, an increase from 40.47% at the end of 2023[29]. - The basic earnings per share for the first quarter of 2024 is 0.04 yuan, down from 0.16 yuan in 2023[30]. - The weighted average return on equity for the first quarter of 2024 is 1.91%, compared to 7.54% in 2023[30]. Business Operations - The company focuses on the full industry chain of tumor prevention, diagnosis, treatment, and rehabilitation, providing comprehensive solutions in medical services and medical devices[17]. - Inkon Life's medical services are primarily provided through its comprehensive and specialized hospitals, focusing on full-cycle treatment for patients[19]. - The company has a strong emphasis on research and development of key equipment and services related to tumor treatment, including proprietary products like the Gamma Knife[19]. - In 2022 and 2023, the medical device segment acquired several companies, enhancing its product diversity with external beam therapy devices and other medical equipment[19]. Compliance and Governance - The company has a commitment to compliance and ethical standards in its securities issuance process, as outlined in its underwriting documents[4]. - The underwriter has confirmed that there are no mutual guarantees or financing arrangements between its controlling shareholders and the issuer's controlling shareholders as of the date of the underwriting report[35]. - The underwriter has established a project approval committee to review securities issuance projects, ensuring that at least two-thirds of the committee members approve the project for it to proceed[39]. - The internal review process includes a quality control report submitted by the lead reviewer, which is essential for the project to be accepted for further review[42]. - The internal review committee consists of at least seven members, and decisions require a two-thirds majority to approve the submission of documents to regulatory authorities[41]. - The issuer's board of directors approved the proposal for a targeted stock issuance on August 12, 2022, with independent directors providing prior approval and clear consent[48]. - The issuer's board held a meeting on December 29, 2023, to approve adjustments to the targeted stock issuance plan, ensuring that related directors abstained from voting[49]. - The underwriter has committed to ensuring that the issuer's application documents do not contain false statements or significant omissions[47]. - The internal review committee has agreed to submit the issuer's application for a targeted stock issuance to the Shenzhen Stock Exchange for review[44]. - The underwriter has established internal control measures to ensure compliance with relevant laws and regulations throughout the underwriting process[41]. - The issuer's board of directors has consistently ensured that independent directors are involved in decisions related to related party transactions[48]. Stock Issuance - The company plans to issue shares to specific investors at a price of 8.99 CNY per share, which is 80% of the average trading price over the last 20 trading days[53]. - The total expected fundraising amount from this issuance is not more than 970 million CNY, which will be used entirely to supplement working capital[58]. - The issuance has been approved by the company's second extraordinary general meeting of 2023 and the annual general meeting of 2023[53]. - The company has confirmed that it does not have any major sensitive issues or legal violations that could affect this issuance[60]. - The company has complied with all relevant laws and regulations regarding the issuance process, including the Company Law and Securities Law[54]. - The issuance will not involve advertising or public solicitation, adhering to the regulations set forth in the Securities Law[55]. - The company has ensured that the use of raised funds aligns with its main business needs and development strategy[58]. - The company has confirmed that there are no significant adverse impacts from the issuance on its independence or operations[58]. - The company has conducted thorough due diligence to ensure compliance with the Registration Management Measures[56]. - The issuance is pending approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission[51]. - The company plans to issue up to 107,897,664 shares, not exceeding 30% of the total share capital prior to the issuance[63]. - The total amount of funds raised from this issuance will not exceed 970 million yuan, which will be used entirely to supplement working capital[63]. - The issuance price is set at 8.99 yuan per share, which is 80% of the average trading price over the last 20 trading days prior to the pricing date[67]. - The lock-up period for the shares acquired by the controlling shareholder will be 36 months from the end of the issuance[68]. - The company’s existing products include gamma knives and various medical devices, which are subject to industry policy changes that could impact business performance[77]. - The company faces risks from intensified competition in the healthcare sector, both from public hospitals and private medical institutions[79]. - The company’s previous fundraising was completed more than 18 months prior to the current issuance date, complying with regulatory requirements[63]. - The issuance will not result in any changes to the controlling shareholder or actual controller of the company[71]. - The funds for the subscription of shares by the controlling shareholder will come from self-owned or legally raised funds, ensuring compliance with regulations[69]. - The company has engaged third-party institutions for legal and accounting services related to this issuance, ensuring compliance with relevant regulations[74]. Market Trends and Risks - The company reported a net profit attributable to shareholders of -364.08 million, -595.92 million, 100.44 million, and 26.23 million for the respective periods, indicating significant volatility in financial performance[85]. - The comprehensive gross margin for the company was 23.94%, 26.53%, 28.57%, and 26.76% over the reporting periods, reflecting fluctuations influenced by various factors[87]. - As of March 31, 2024, the company's goodwill amounted to 693.29 million, representing 49.01% of the net assets, indicating a high proportion of goodwill on the balance sheet[88]. - Accounts receivable increased to 265.27 million by the end of the reporting period, with a bad debt provision of 52.96 million, highlighting potential risks in receivables management[89]. - The company completed the acquisition of 100% equity in Guangci Hospital and several other medical device companies, which may pose integration risks due to cultural and operational differences[92]. - The company experienced a year-on-year decline in net profit of 33.69% and 38.55% for the first quarter of 2024, primarily due to increased share-based payment expenses[85]. - The company faces risks related to administrative penalties if it fails to comply with relevant laws and regulations in its operations[83]. - The company is exposed to public relations crisis risks that could significantly damage its brand image and financial performance[82]. - The company’s reliance on expert-level physicians and continuous product innovation is critical for maintaining competitive advantage in the medical services and device sectors[81]. - The company’s stock price is subject to fluctuations influenced by macroeconomic conditions, capital market trends, and various unforeseen events[96]. Industry Insights - The medical service market in China has grown from CNY 199.80 billion in 2010 to CNY 853.27 billion in 2022, with a compound annual growth rate (CAGR) of 12.86%[97]. - In 2022, the number of private hospitals in China reached 25,230, representing a CAGR of approximately 8.21% from 2015, while public hospitals decreased to 11,746[99]. - The proportion of private hospitals in total hospital numbers increased from 50.00% in 2015 to 68.23% in 2022[99]. - The market size of China's oncology treatment industry grew from CNY 231.4 billion in 2015 to CNY 454.4 billion in 2021, with a CAGR of 11.90%[103]. - The private oncology medical service market is projected to grow from CNY 63 billion in 2022 to CNY 247 billion by 2030, with a CAGR of 18.62%[104]. - China's medical device market size was approximately CNY 909.01 billion in 2021 and is expected to reach CNY 2,492.41 billion by 2030, with a CAGR of 11.9%[108]. - The revenue from radiation therapy services in Chinese oncology hospitals increased from CNY 272 billion in 2016 to CNY 517 billion in 2021, with a CAGR of 13.71%[111]. - The penetration rate of radiation therapy in China was only 23% in 2015, compared to 60% in the United States, indicating significant growth potential[113]. - The number of radiation therapy devices per million people in China was only 2.7 in 2019, compared to 14.4 in the United States, highlighting a resource shortage[113]. - By the end of 2020, China added 1,552 new radiotherapy devices, including proton therapy systems and linear accelerators, contributing to a projected market size of 6.33 billion yuan by 2030[115]. - The medical imaging equipment market in China reached 53.7 billion yuan in 2020, with an expected growth to nearly 110 billion yuan by 2030, reflecting a compound annual growth rate of 7.3%[118]. Research and Development - The company has completed acquisitions of several firms, enhancing its R&D capabilities and product offerings, including leading technologies in stereotactic radiosurgery and digital mammography[123]. - The company has established a digital health management platform, achieving 100% patient follow-up coverage and enhancing rehabilitation management services[126]. - The company has expanded its product line to cover four major application scenarios, including radiation therapy and chronic disease treatment, with a total of 14 registered trademarks and 154 patents as of March 31, 2024[129]. Underwriting Process - The underwriting representative for the stock issuance is designated as Mao Ning and Chen Cong[137]. - The underwriting agreement was signed between Guotai Junan Securities Co., Ltd. and Yinkang Life Science Technology Co., Ltd.[137]. - The underwriting representative is responsible for coordinating with regulatory bodies such as the China Securities Regulatory Commission and Shenzhen Stock Exchange[137]. - The underwriting representative must conduct due diligence on the issuer's application documents and verify any significant discrepancies with professional opinions[137]. - The issuer is responsible for covering the costs of hiring additional professional services if needed[137]. - The underwriting representative's rights must comply with the relevant regulations and the underwriting agreement[138].